Cargando…

Biomarker testing in MCI patients—deciding who to test

BACKGROUND: We aimed to derive an algorithm to define the optimal proportion of patients with mild cognitive impairment (MCI) in whom cerebrospinal fluid (CSF) testing is of added prognostic value. METHODS: MCI patients were selected from the Amsterdam Dementia Cohort (n = 402). Three-year progressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Maurik, Ingrid S., Rhodius-Meester, Hanneke F. M., Teunissen, Charlotte E., Scheltens, Philip, Barkhof, Frederik, Palmqvist, Sebastian, Hansson, Oskar, van der Flier, Wiesje M., Berkhof, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792312/ https://www.ncbi.nlm.nih.gov/pubmed/33413634 http://dx.doi.org/10.1186/s13195-020-00763-7

Ejemplares similares

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Life satisfaction across the entire trajectory of Alzheimer's disease: A mediation analysis
por: Mank, Arenda, et al.
Publicado: (2022)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2017)

Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2020)

Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
por: Mank, Arenda, et al.
Publicado: (2022)

Determinants of informal care time, distress, depression, and quality of life in care partners along the trajectory of Alzheimer's disease
por: Mank, Arenda, et al.
Publicado: (2023)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Evaluating combinations of diagnostic tests to discriminate different dementia types
por: Bruun, Marie, et al.
Publicado: (2018)

Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage
por: Poil, Simon-Shlomo, et al.
Publicado: (2013)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project
por: Visser, Leonie N. C., et al.
Publicado: (2020)

Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Survival in memory clinic cohort is short, even in young-onset dementia
por: Rhodius-Meester, Hanneke Frederica Maria, et al.
Publicado: (2019)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease
por: Skillbäck, Tobias, et al.
Publicado: (2017)

A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
por: Mank, Arenda, et al.
Publicado: (2022)

Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier
por: Tolonen, Antti, et al.
Publicado: (2018)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia
por: van Straaten, Elisabeth CW, et al.
Publicado: (2012)

Development and design of a diagnostic report to support communication in dementia: Co‐creation with patients and care partners
por: van Gils, Aniek M., et al.
Publicado: (2022)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

cCOG: A web‐based cognitive test tool for detecting neurodegenerative disorders
por: Rhodius‐Meester, Hanneke F.M., et al.
Publicado: (2020)

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
por: Thijssen, Elisabeth H., et al.
Publicado: (2021)

Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics
por: Thorlacius-Ussing, Gorm, et al.
Publicado: (2021)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort
por: Muurling, Marijn, et al.
Publicado: (2020)

Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study
por: van Gils, Aniek M, et al.
Publicado: (2021)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Computer-assisted prediction of clinical progression in the earliest stages of AD
por: Rhodius-Meester, Hanneke F.M., et al.
Publicado: (2018)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline
por: Verfaillie, Sander C. J., et al.
Publicado: (2018)

Differential diagnosis of neurodegenerative diseases using structural MRI data
por: Koikkalainen, Juha, et al.
Publicado: (2016)

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
por: Babapour Mofrad, Rosha, et al.
Publicado: (2021)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ue4artgeb36tqvv7loildtig40